GBT Reports Second Quarter 2021 Financial Results
August 03, 2021 16:05 ET
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing...
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
July 27, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2021 financial results on...
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
July 22, 2021 07:00 ET
|
Global Blood Therapeutics, Inc.
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta® (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in...
GBT Announces New Employment Inducement Grants
July 09, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT’s board of...
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
June 15, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and...
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
June 14, 2021 07:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and...
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
June 11, 2021 03:00 ET
|
Global Blood Therapeutics, Inc.
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the...
GBT Announces New Employment Inducement Grants
June 04, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of...
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 08:00 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd...
GBT présentera prochainement ses données à l’occasion du Congrès virtuel 2021 de l'Association européenne d'hématologie (EHA)
May 12, 2021 10:05 ET
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Californie, 12 mai 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ : GBT) a annoncé aujourd'hui que six abstracts relatifs à son programme de...